Anixa Biosciences’ (ANIX) Buy Rating Reiterated at HC Wainwright

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 142.21% from the company’s previous close.

Anixa Biosciences Stock Performance

ANIX opened at $2.89 on Wednesday. Anixa Biosciences has a twelve month low of $2.14 and a twelve month high of $5.13. The firm has a market cap of $92.50 million, a P/E ratio of -7.81 and a beta of 0.89. The business has a 50 day moving average price of $2.58 and a 200 day moving average price of $3.29.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings results on Tuesday, June 4th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. As a group, analysts anticipate that Anixa Biosciences will post -0.43 earnings per share for the current fiscal year.

Insider Transactions at Anixa Biosciences

In other news, Director Lewis H. Titterton, Jr. acquired 10,738 shares of the stock in a transaction dated Friday, June 7th. The shares were acquired at an average cost of $2.52 per share, for a total transaction of $27,059.76. Following the completion of the transaction, the director now owns 848,775 shares in the company, valued at approximately $2,138,913. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Amit Kumar acquired 25,000 shares of the stock in a transaction dated Friday, June 7th. The shares were acquired at an average cost of $2.41 per share, for a total transaction of $60,250.00. Following the completion of the transaction, the chief executive officer now owns 516,925 shares in the company, valued at approximately $1,245,789.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lewis H. Titterton, Jr. acquired 10,738 shares of the stock in a transaction dated Friday, June 7th. The shares were purchased at an average price of $2.52 per share, for a total transaction of $27,059.76. Following the completion of the transaction, the director now owns 848,775 shares of the company’s stock, valued at approximately $2,138,913. The disclosure for this purchase can be found here. Insiders acquired a total of 42,723 shares of company stock worth $104,261 over the last three months. 22.60% of the stock is currently owned by insiders.

Institutional Trading of Anixa Biosciences

A number of large investors have recently bought and sold shares of ANIX. International Assets Investment Management LLC grew its position in Anixa Biosciences by 274.6% in the fourth quarter. International Assets Investment Management LLC now owns 54,320 shares of the company’s stock valued at $2,110,000 after acquiring an additional 39,820 shares during the period. Simplicity Wealth LLC bought a new stake in Anixa Biosciences in the first quarter valued at $44,000. Staley Capital Advisers Inc. bought a new stake in Anixa Biosciences in the first quarter valued at $31,000. Finally, Virtu Financial LLC grew its position in Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after acquiring an additional 5,183 shares during the period. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.